Mantle Cell Lymphoma: Updates on Diverging Therapeutic Strategies by TP53 Status
Journal of the National Comprehensive Cancer Network · 2026-05 · 24 (Supplement) · 30-33
DOI: 10.6004/jnccn.2026.5009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-05. Verfasst von Paolo F. Caimi und 1 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Presentations at the NCCN 2026 Annual Conference highlighted how strongly TP53 status now shapes treatment strategies in classical mantle cell lymphoma (MCL). In newly diagnosed TP53 wild-type disease, historical support for autologous stem cell transplantation (ASCT) in first remission is being challenged by newer data suggesting that patients who achieve deep responses with BTK inhibitor–containing therapy or undetectable measurable residual disease (MRD) may derive little incremental benefit from transplant. In contrast, TP53 -mutated disease remains a biologically distinct, high-risk subgroup with poor outcomes after intensive chemoimmunotherapy and no clear role for ASCT in first remission. Instead, novel combinations, cellular therapy, and bispecific antibodies are emerging as more relevant strategies, although durability remains a concern. Together, the presentations underscored a broader shift in MCL away from uniform treatment intensification and toward biologically and response-adapted care.
Zitieren
APA
Caimi, P. F., & LaCasce, A. S. (2026). Mantle Cell Lymphoma: Updates on Diverging Therapeutic Strategies by TP53 Status. Journal of the National Comprehensive Cancer Network, 24(Supplement), 30-33. https://doi.org/10.6004/jnccn.2026.5009
Vancouver
Caimi PF, LaCasce AS. Mantle Cell Lymphoma: Updates on Diverging Therapeutic Strategies by TP53 Status. Journal of the National Comprehensive Cancer Network. 2026;24(Supplement):30-33. doi:10.6004/jnccn.2026.5009
BibTeX
@article{Caimi2026,
author = {Caimi, Paolo F. and LaCasce, Ann S.},
title = {Mantle Cell Lymphoma: Updates on Diverging Therapeutic Strategies by TP53 Status},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2026},
volume = {24},
number = {Supplement},
pages = {30--33},
doi = {10.6004/jnccn.2026.5009}
}
EUVIMED